107. Juvenile idiopathic arthritis Clinical trials / Disease details


Clinical trials : 441 Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-001086-34-ES
(EUCTR)
21/10/200520/06/2005A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los 6 meses versus a los 12 meses, en pacientes con Artritis Idiopática Juvenil (AIJ) en remisión clínica - MTX withdrawal studyA randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los 6 meses versus a los 12 meses, en pacientes con Artritis Idiopática Juvenil (AIJ) en remisión clínica - MTX withdrawal study The present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 months after documentation of remission on medication. In group 2 treatment with MTX will be discontinued later than 12 mpnths after documentation of remission on medication.Trade Name: Metotrexato
Product Name: Methotrexate
Trade Name: Methotrexate
Product Name: Methotrexate
Product Code: L01BA01
Istituto Giannina Gaslini-PRINTONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Denmark;Spain;Italy
2EUCTR2005-001086-34-DK
(EUCTR)
21/09/200519/08/2005A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clincal remission - MTX withdrawal studyA randomised trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clincal remission - MTX withdrawal study The present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 months after documentation of remission on medication. In group 2 treatment with MTX will be discontinued later than 12 months after documentation of remission on medicationProduct Name: Methotrexate
Product Code: L01BA01
Product Name: Methotrexate
Product Code: L01BA01
ISTITUTO GIANNINA GASLINI-PRINTONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
200Denmark;Spain;Italy